Point72 Asset Management
LXEO icon

Point72 Asset Management’s Lexeo Therapeutics LXEO Stock Holding History

Point72 Asset Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.65M Sell
1,680,449
-214,273
-11% -$1.52M 0.01% 1283
2025
Q4 		$18.8M Sell
1,894,722
-47,127
-2% -$430K 0.02% 931
2025
Q3 		$12.9M Buy
1,941,849
+1,293,969
+200% +$6.26M 0.02% 705
2025
Q2 		$2.6M Sell
647,880
-450,263
-41% -$1.48M 0.01% 1190
2025
Q1 		$3.81M Buy
1,098,143
+347,908
+46% +$1.54M 0.01% 1026
2024
Q4 		$4.94M Buy
750,235
+379,828
+103% +$2.99M 0.01% 949
2024
Q3 		$3.35M Buy
+370,407
New +$4.42M 0.01% 1001

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management's LXEO Position: Q1 2026 in Review

Point72 Asset Management reduced its Lexeo Therapeutics (LXEO) stake by 11% in Q1 2026, selling an estimated $1.52M and leaving 1,680,449 shares worth $9.65M. The position accounts for 0.01% of the portfolio, ranked #1283.

Point72 Asset Management first reported a position in LXEO in Q3 2024 and has held it in 7 quarters since. The position peaked at $18.8M in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Point72 Asset Management held 1,680,449 shares of Lexeo Therapeutics worth $9.65M as of Q1 2026.
  • Point72 Asset Management sold 214,273 Lexeo Therapeutics shares in Q1 2026, an estimated $1.52M.
  • Lexeo Therapeutics made up 0.01% of Point72 Asset Management's portfolio in Q1 2026, its #1283 holding.
  • Point72 Asset Management first reported a position in Lexeo Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Point72 Asset Management's Lexeo Therapeutics position peaked at $18.8M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.